Catalent Rises on Report Lonza Group Offered to Buy ItBy
No deal has been reached between the companies, and the negotiations may not continue, according to Reuters. Swiss-based Lonza supplies products such as stem cells to biotechnology and pharmaceutical companies.
Catalent gained 4.1 percent to $29.66 at the close in New York, after earlier touching $32.24. The stock has risen 18 percent this year.
Thomas Castellano, a spokesman for Somerset, New Jersey-based Catalent, declined to comment on what he said the company views as merger and acquisition rumors. Catalent had $1.83 billion in sales last year, with almost two-thirds coming from its oral technologies unit.
(A previous version of this story corrected the share history in the third paragraph.)
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.